


*“Compound-kinase binding affinity prediction with
confidence guarantees”*

Davor Oršolić, Tomislav Šmuc


Introduction

- Rapid development in machine learning and computer science allows for efficient profiling of enormous chemical spaces.
- Protein kinase inhibitors are one of the most popular groups of pharmacologically promising compounds.
- IDG-DREAM Drug-Kinase Binding Prediction Challenge




Introduction


A. Dataset collection and preprocessing




B. Representation of chemical spaces




C. Building the model



D-E. Scoring metrics; Applicability domain





Inductive conformal predictor (ICP)

$$Z = \{(x_1, y_1), \dots, (x_n, y_n)\} \quad \begin{cases} Z^t = \{(x_1, y_1), \dots, (x_m, y_m)\} \\ Z^c = \{(x_{m+1}, y_{m+1}), \dots, (x_n, y_n)\} \end{cases}$$

For every calibration sample $(x_i, y_i) \in Z^c$

- Predict output value $\hat{y}_i = h_Z(x_i)$
- Calculate non-conformity scores (α_i)

Non-conformity function:

$$\alpha_i = |y_i - \hat{y}_i|$$

For every tentative label \tilde{y} , compute non-conformity score and p-value:

$$p(\tilde{y}) = \frac{\#\{z_i \in Z^c \mid \alpha_i \geq \alpha_{\tilde{y}}\} + 1}{|Z^c| + 1}, \quad p(\tilde{y}) < \delta$$

Given a significance level δ and a set of calibration scores $S = \{\alpha_1, \dots, \alpha_n\}$, locate the smallest $\alpha_{s(\delta)} \in S$ that satisfies the equation:

$$\frac{\#\{z_i \in Z^c \mid \alpha_i < \alpha_{s(\delta)}\} + 1}{|Z^c| + 1} \geq 1 - \delta$$


Inductive conformal predictor (ICP)

$$\frac{\#\{z_i \in Z^c \mid \alpha_i < \alpha_s(\delta)\} + 1}{|Z^c| + 1} \geq 1 - \delta$$

$$\Gamma_j^\delta = \hat{y}_j \pm \alpha_s(\delta)$$

Compute α_x scores for every tentative \hat{y}_x label?

$$\Gamma_j^\delta = h_z(x_j) \pm \alpha_s(\delta)$$



ICP + Normalisation measure

$$\frac{\#\{z_i \in Z^c \mid \alpha_i < \alpha_s(\delta)\} + 1}{|Z^c| + 1} \geq 1 - \delta$$

$$\Gamma_j^\delta = \hat{y}_j \pm \frac{\alpha_s(\delta)}{\sigma_j}$$


Where σ_j is an estimate of the accuracy of the underlying model for \hat{y}_j .

Other *normalisation* methods include:

$$\alpha_i = \left| \frac{y_i - \hat{y}_i}{\gamma + \lambda_j^k} \right|$$

$$\alpha_i = \left| \frac{y_i - \hat{y}_i}{\gamma + \xi_j^k} \right|$$


$$\Gamma_j^\delta = h_z(x_j) \pm \frac{\alpha_s(\delta)}{\sigma_j}$$



dAD

Dynamic Applicability Domain


Protein kinase domain sequence t-SNE plot



$$T \subset T^t, |T| = q$$
$$\forall t^{(i)} \in T \text{ and } \forall t^{(j)} \in T^t \setminus T$$
$$s(t^{(i)}, t) \geq s(t^{(j)}, t)$$

$$Z^c = (x^{(ij)}, y^{(ij)}) : x^{(ij)} \subset (C, T) \text{ and } \exists y^{(ij)} \subset Y^t$$

Compound space



$$C \subset C^t, |C| = k$$
$$\forall c^{(i)} \in C \text{ and } \forall c^{(j)} \in C^t \setminus C$$
$$s(c^{(i)}, c) \geq s(c^{(j)}, c)$$

dAD

Dynamic Applicability Domain

$$Z = \{(x_1, y_1), \dots, (x_r, y_r)\}$$

$$Z^c = \{(x^{(ij)}, y^{(ij)}) : x^{(ij)} \in (C, T) \text{ and } \mathcal{H}y^{(ij)} \in Y^a\}$$

$$k=250; q=25$$

$$\alpha^{cal} = \alpha_i^{nn} = |y_i^{cal} - \hat{y}^{nn}|, \alpha^{nn} \in S^{nn}$$

$$\alpha^{cal} = \alpha_i^{cv} = |y_i^{cal} - \hat{y}^{cv}|, \alpha^{cv} \in S^{cv}$$

$$\alpha_i^x = |y_i^{cal} - \hat{y}|, \alpha^x \in S^x$$

Where $x^{(ij)}$ represents a tuple $(c^{(i)}, t^{(j)})$.

For every new test sample x_i

- Predict output value $\hat{y}_i = h_z(x_i)$;
- Locate conformity region in the training space separately for compound (C) and target (T) space;
- Calculate non-conformity scores (α_i^c) for calibration samples based on cross-validation predictions (CV) or the sample mean (NN);
- Calculate non-conformity scores for x_i towards each calibration example, (α_x).


Given a significance level δ and sets of non-conformity scores for calibration samples S_i and test sample S_x , locate the smallest $\alpha_{i(\delta)}$ that satisfies the equation:

$$\frac{\#\{z^{(ij)} \in Z^c \mid \alpha_x < \alpha_{i(\delta)}\} + 1}{|Z^c| + 1} \geq 1 - \delta$$

Bioactivity space




We test this approach on four testing scenarios:

- I. contains new compound-target pairs, **S1**;
- II. contains new compound-target pairs with compounds never seen in the training set, **S2**;
- III. contains new compound-target pairs with targets never seen in the training set, **S3**;
- IV. contains never seen compounds nor targets in the training set, **S4**.



dAD

Dynamic Applicability Domain



Baseline comparison

SCKBA

SCKBA									
Approach	SX	Median		Error rates per confidence level (%)					
		α_g	#calib	75%	80%	85%	90%	95%	99%
Shafer & Vovk (7)	S1	0.86	4000	21.83	16.34	11.91	6.56	3.66	0.76
	S2	0.86	4000	40.64	35.08	30.27	21.60	12.41	2.57
	S3	0.86	4000	35.49	31.73	26.02	18.95	11.43	3.91
	S4	0.86	4000	86.17	84.50	81.83	80.00	72.83	49.17
Papadopoulos (8)	S1	2.41	4000	7.02	4.43	3.21	2.14	1.37	0.31
	S2	1.66	4000	21.93	17.86	14.65	10.80	7.17	1.07
	S3	2.33	4000	10.83	7.67	6.32	4.21	2.41	0.15
	S4	1.47	4000	78.5	73.83	68.33	59.67	41.00	7.33
Papadopoulos (9)	S1	1.02	4000	19.69	15.73	10.84	7.33	5.50	1.68
	S2	1.13	4000	30.16	24.39	19.68	13.69	7.49	1.39
	S3	1.55	4000	22.71	18.35	14.74	10.68	5.86	1.20
	S4	3.32	4000	33.83	25.17	17.17	6.33	2.67	0.00
Papadopoulos (10)	S1	0.85	4000	22.60	16.49	12.98	7.79	4.12	1.22
	S2	0.55	4000	43.10	37.75	32.09	25.67	17.11	5.67
	S3	0.95	4000	32.18	27.37	22.71	16.54	10.53	3.01
	S4	0.78	4000	87.83	85.83	84.33	81.50	76.5	55.17
dAD (NN)	S1	1.85	315	1.87 (.73)	1.65 (.74)	0.79 (.77)	1.00 (.76)	0.62 (.74)	0.00 (.63)
	S2	1.78	261	8.76 (.74)	6.72 (.70)	3.54 (.63)	2.94 (.58)	1.28 (.59)	0.36 (.60)
	S3	1.65	268	11.90 (.69)	10.11 (.71)	8.07 (.73)	6.03 (.77)	4.76 (.79)	1.03 (.73)
	S4	1.79	259	70.70 (.26)	68.40 (.38)	60.47 (.56)	52.27 (.84)	39.22 (.98)	12.69 (.87)
dAD (CV)	S1	1.61	315	1.73 (.62)	1.79 (.60)	1.08 (.56)	1.23 (.50)	0.42 (.36)	0.00 (.20)
	S2	1.60	266	9.31 (.61)	8.01 (.57)	4.75 (.50)	3.23 (.46)	1.34 (.40)	0.34 (.31)
	S3	1.43	268	12.71 (.64)	12.02 (.63)	9.74 (.59)	7.65 (.55)	3.81 (.43)	0.00 (.21)
	S4	1.69	259	70.67 (.25)	69.20 (.37)	60.55 (.55)	52.3 (.76)	45.41 (.69)	10.42 (.40)



Benchmark datasets (KI)

Dataset	Approach	Median		Error rates per confidence level (%)					
		α_g	#calib	75%	80%	85%	90%	95%	99%
Davis	Shafer & Vovk (7)	0.75	1500	23.86	19.28	14.43	9.77	4.13	0.76
	Papadopoulos (8)	1.92	1500	13.12	10.36	7.63	5.32	2.76	0.91
	Papadopoulos (9)	0.76	1500	23.13	18.46	13.61	9.03	3.73	0.65
	Papadopoulos (10)	0.76	1500	26.08	21.77	17.61	12.78	6.28	1.36
	dAD (CV)	1.10	502	3.56 (.34)	3.33 (.52)	3.30 (.71)	3.04 (.80)	2.21 (.77)	0.87 (.46)
	dAD (NN)	1.30	502	3.43 (.33)	3.25 (.52)	3.24 (.71)	2.81 (.83)	1.87 (.91)	0.48 (.91)
KIBA	Shafer & Vovk (7)	0.58	3000	23.96	19.08	14.73	9.41	4.79	0.94
	Papadopoulos (8)	2.00	3000	8.65	6.92	5.55	3.82	2.34	1
	Papadopoulos (9)	0.58	3000	23.62	18.96	14.51	9.42	4.66	0.91
	Papadopoulos (10)	0.58	3000	24.85	20.01	15.73	10.23	5.77	1.46
	dAD (CV)	1.30	1661	3.77 (.73)	2.62 (0.80)	1.99 (.87)	1.04 (.91)	0.39 (.84)	0.09 (.46)
	dAD (NN)	1.47	1661	3.60 (.72)	2.46 (.81)	1.85 (.90)	0.96 (.96)	0.39 (.98)	0.1 (.93)
BindingDB	Shafer & Vovk (7)	1.26	3000	23.36	28.85	13.08	8.84	5.00	0.84
	Papadopoulos (8)	2.09	3000	13.48	11.37	8.84	6.9	5.13	3.85
	Papadopoulos (9)	0.84	3000	37.41	34.79	31.12	27.28	23.01	12.88
	Papadopoulos (10)	1.24	3000	25.52	21.6	16.42	11.78	7.45	1.83
	dAD (CV)	1.55	133	9.06 (.58)	6.72 (.55)	5.45 (.49)	3.54 (.44)	1.86 (.39)	0.80 (.27)
	dAD (NN)	1.33	133	8.64 (.73)	6.08 (.71)	4.58 (.68)	3.09 (.67)	1.54 (.65)	0.61 (.48)
ChEMBL	Shafer & Vovk (7)	0.91	3000	24.62	19.27	13.92	9.40	4.51	0.99
	Papadopoulos (8)	2.04	3000	8.01	6.43	4.62	3.28	1.83	0.69
	Papadopoulos (9)	1.18	3000	19.79	16.01	12.13	8.77	4.91	1.66
	Papadopoulos (10)	0.91	3000	25.41	20.49	15.13	10.63	5.86	1.77
	dAD (CV)	1.45	253	5.18 (.74)	3.70 (.68)	2.35 (.62)	1.47 (.53)	0.62 (.40)	0. (.15)
	dAD (NN)	1.69	253	4.38 (.86)	3.11 (.86)	1.85 (.86)	1.13 (.86)	0.43 (.83)	0.15 (.57)

DTC (GPCR; SSRI)


Dataset	Approach	Median		Error rates per confidence level (%)					
		α_g	#calib	75%	80%	85%	90%	95% CI	99%
GPCR	Shafer & Vovk (7)	1.13	1500	25.02	18.85	14.29	10.00	5.16	1.07
	Papadopoulos (8)	2.09	1500	13.62	11.24	9.02	7.46	6.02	4.82
	Papadopoulos (9)	1.15	1500	24.15	18.53	14.29	9.19	5.13	0.87
	Papadopoulos (10)	1.14	1500	25.28	18.93	14.93	10.44	6.18	1.28
	dAD (CV)	2.14	874	3.69 (.84)	2.98 (.81)	1.84 (.77)	1.12 (.70)	0.54 (.59)	0.1 (.58)
	dAD (NN)	2.25	874	3.72 (.94)	2.82 (.93)	1.77 (.90)	1.09 (.85)	0.45 (.78)	0.08 (.75)
SSRI	Shafer & Vovk (7)	1.05	1500	24.7	19.13	14.59	9.53	4.25	1.05
	Papadopoulos (8)	2.09	1500	10.21	8.17	6.15	3.83	2.06	1.24
	Papadopoulos (9)	1.13	1500	25.83	21.09	17.26	12.06	6.6	2.41
	Papadopoulos (10)	1.05	1500	24.57	19.69	15.33	9.87	4.7	1.21
	dAD (CV)	1.86	234	4.17 (.68)	3.15 (.63)	4.47 (.53)	1.56 (.47)	0.66 (.40)	0.23 (.21)
	dAD (NN)	2.02	234	3.98 (.89)	2.99 (.85)	2.09 (.81)	1.38 (.74)	0.63 (.67)	0.11 (.49)

Baseline comparison




Baseline comparison





A) Test scenarios (S1-S4)



B) Benchmarks



Baseline comparison



dAD (CV) vs. dAD (NN)

Concluding remarks

- **dAD** depends on a sample specific calibration set;
- Calibration set is defined by the conformity of test compounds and targets individually;
- Output consists of sample specific prediction regions, with **no** need for additional **normalisation measures**;
- Provides robust guarantees for suggested prediction regions, and more accurately reflects model performance in the training area close to the test sample;
- Proved to be more **effective for** challenging prediction settings reflecting **real use-case scenarios** (S2 and S3).

Acknowledgements:

Research Cooperability Program of the Croatian Science Foundation, funded by the European Union from the European Social Fund under the Operational Programme Efficient Human Resources 2014-2020, through the **Grant 8525: Augmented Intelligence Workflows for Prediction, Discovery, and Understanding in Genomics and Pharmacogenomics.**



Croatian Government and the European Union (European Regional Development Fund — the Competitiveness and Cohesion Operational Program), through the project Bioprospecting of the Adriatic Sea (KK.01.1.1.01.0002), granted to *The Scientific Centre of Excellence for Marine Bioprospecting — BioProCro.*



Thank you for your attention!